Monitoring Crohn’s disease during anti-TNF-α therapy: validation of the magnetic resonance enterography global score (MEGS) against a combined clinical reference standard

European Radiology

Volumn 26, Issue 7, 2016, Pages 2107-2117

  Prezzi, Davide ^a,c   Bhatnagar, Gauraang ^a   Vega, Roser ^b   Makanyanga, Jesica ^a   Halligan, Steve ^a   Taylor, Stuart Andrew ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Biological therapy; Crohn s disease; Enterography; Magnetic resonance imaging; Therapeutic monitoring

Indexed keywords

ADALIMUMAB; GADOLINIUM; INFLIXIMAB; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; COHORT ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAGNETIC RESONANCE ENTEROGRAPHY; MAGNETIC RESONANCE ENTEROGRAPHY GLOBAL SCORE; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RADIOLOGIST; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; ADOLESCENT; DIAGNOSTIC IMAGING; GASTROINTESTINAL TRACT; PROCEDURES; REPRODUCIBILITY; TREATMENT OUTCOME; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CROHN DISEASE; FEMALE; GASTROINTESTINAL TRACT; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84944571689     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-015-4036-1     Document Type: Article

References (29)

1. Mayberry JF, Lobo A, Ford AC, Thomas A (2013) NICE clinical guideline (CG152): the management of Crohn’s disease in adults, children and young people. Aliment Pharmacol Ther 37:195–203
2. D’Haens GR, Sartor RB, Silverberg MS, Petersson J, Rutgeerts P (2014) Future directions in inflammatory bowel disease management. J Crohns Colitis 8:726–734
3. De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G (2013) Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis 19:429–444
4. D’Haens G, Baert F, van Assche G et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371:660–667
5. Ben-Horin S, Chowers Y (2011) Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 33:987–995
6. Panes J, Bouhnik Y, Reinisch W et al (2013) Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 7:556–585
7. Steward MJ, Punwani S, Proctor I et al (2012) Non-perforating small bowel Crohn’s disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index. Eur J Radiol 81:2080–2088
8. Rimola J, Ordás I, Rodriguez S et al (2011) Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 17:1759–1768
9. Ordás I, Rimola J, Rodríguez S et al (2014) Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 146:374.e1–382.e1
10. Van Assche G, Herrmann KA, Louis E et al (2013) Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn’s disease. J Crohns Colitis 7:950–957
11. Tielbeek JA, Löwenberg M, Bipat S et al (2013) Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn’s disease. Inflamm Bowel Dis 19:1943–1950
12. Makanyanga JC, Pendsé D, Dikaios N et al (2014) Evaluation of Crohn’s disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol 24:277–287
13. (2013) Biological therapies audit sub group. National clinical audit report of biological therapies. Adult national report. UK IBD audit. Royal College of Physicians
14. Plumb AA, Menys A, Russo E et al (2015) Magnetic resonance imaging-quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn’s disease. Aliment Pharmacol Ther 42:343–355
15. Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55:749–753
16. Lauenstein TC, Schneemann H, Vogt FM, Herborn CU, Ruhm SG, Debatin JF (2003) Optimization of oral contrast agents for MR imaging of the small bowel. Radiology 228:279–283
17. Ajaj WM, Lauenstein TC, Pelster G et al (2005) Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut 54:257–263
18. Van Assche G, Dignass A, Panes J et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 4:7–27
19. Messaris E, Chandolias N, Grand D, Pricolo V (2010) Role of magnetic resonance enterography in the management of Crohn disease. Arch Surg 145:471–475
20. Hafeez R, Punwani S, Boulos P et al (2011) Diagnostic and therapeutic impact of MR enterography in Crohn’s disease. Clin Radiol 66:1148–1158
21. Tielbeek JA, Makanyanga JC, Bipat S et al (2013) Grading Crohn disease activity with MRI: interobserver variability of MRI features, MRI scoring of severity, and correlation with Crohn disease endoscopic index of severity. AJR Am J Roentgenol 201:1220–1228
22. Tielbeek JA, Bipat S, Boellaard TN, Nio CY, Stoker J (2014) Training readers to improve their accuracy in grading Crohn’s disease activity on MRI. Eur Radiol 24:1059–1067
23. Hordonneau C, Buisson A, Scanzi J et al (2014) Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease: validation of quantitative index of activity. Am J Gastroenterol 109:89–98
24. Pariente B, Mary JY, Danese S et al (2015) Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology 148:52.e3–63.e3
25. Rimola J, Planell N, Rodríguez S et al (2015) Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol 110:432–440
26. Zappa M, Stefanescu C, Cazals-Hatem D et al (2011) Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn’s disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis 17:984–993
27. Rimola J, Rodriguez S, García-Bosch O et al (2009) Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut 58:1113–1120
28. Taylor SA, Punwani S, Rodriguez-Justo M et al (2009) Mural Crohn disease: correlation of dynamic contrast-enhanced MR imaging findings with angiogenesis and inflammation at histologic examination--pilot study. Radiology 251:369–379
29. Ziech ML, Bipat S, Roelofs JJ et al (2011) Retrospective comparison of magnetic resonance imaging features and histopathology in Crohn’s disease patients. Eur J Radiol 80:e299–e305